SPA
ENTA icon

Sherbrooke Park Advisers’s Enanta Pharmaceuticals ENTA Stock Holding History

Sherbrooke Park Advisers’s Portfolio ENTA Stock Details ENTA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-12,538
Closed -$94.8K – 573
2025
Q2 		$94.8K Sell
12,538
-8,437
-40% -$50.8K 0.04% 466
2025
Q1 		$116K Sell
20,975
-12,476
-37% -$77.1K 0.05% 496
2024
Q4 		$192K Buy
+33,451
New +$321K 0.06% 598
2023
Q4 		– Sell
-10,100
Closed -$113K – 536
2023
Q3 		$113K Buy
+10,100
New +$163K 0.04% 445

Other funds holding ENTA

FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
KAM
Krensavage Asset Management New York $256M AUM 69.63% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Sherbrooke Park Advisers's ENTA Position: Q3 2025 in Review

Sherbrooke Park Advisers sold out of Enanta Pharmaceuticals (ENTA) in Q3 2025, closing a stake of 12,538 shares — an estimated $94.8K sold.

Sherbrooke Park Advisers first reported a position in ENTA in Q3 2023 and held it in 4 quarters. The position peaked at $192K in Q4 2024. 122 funds tracked by Wall St. Rank hold ENTA as of Q3 2025.

  • Sherbrooke Park Advisers reported no remaining Enanta Pharmaceuticals position as of Q3 2025 after selling out during the quarter.
  • Sherbrooke Park Advisers sold 12,538 Enanta Pharmaceuticals shares in Q3 2025, an estimated $94.8K.
  • Sherbrooke Park Advisers first reported a position in Enanta Pharmaceuticals in Q3 2023 and held it in 4 quarters.
  • Sherbrooke Park Advisers's Enanta Pharmaceuticals position peaked at $192K in Q4 2024.
  • 122 funds tracked by Wall St. Rank held Enanta Pharmaceuticals as of Q3 2025.

Based on Sherbrooke Park Advisers's 13F filing for Q3 2025, filed 14 Nov 2025.